Department of Pathology Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
J Thorac Oncol. 2013 Mar;8(3):322-8. doi: 10.1097/JTO.0b013e31827db604.
ALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leading to anaplastic lymphoma kinase (ALK) overexpression and predicting response to targeted therapy. Fluorescence in situ hybridization (FISH) is the standard procedure for detection of ALK rearrangements in lung ACA but requires specialized equipment and expertise. Immunohistochemistry (IHC) for ALK protein overexpression is a promising screening modality, with reports of newer antibodies showing excellent sensitivity and specificity for ALK-rearranged lung ACA.
In this study, we analyzed ALK IHC (5A4 clone) in 186 cases from our clinical service and compared it with ALK FISH and EGFR and KRAS mutation status.
Twelve cases had concordant ALK protein overexpression and ALK rearrangement by FISH. Three ALK-rearranged cases lacked ALK protein expression. Of these discrepant cases, one had a coexisting EGFR mutation and a subtle atypical ALK rearrangement manifested as a break in the 5' centromeric portion of the FISH probe. One case had a concurrent BRAF mutation. Follow-up testing on a metastasis revealed absence of the ALK rearrangement, with persistent BRAF mutation. In one ALK-rearranged protein negative case, very limited tissue remained for ALK IHC, raising the possibility of false negativity because of protein expression heterogeneity. Importantly, ALK protein expression was detected in one case initially thought not to have an ALK rearrangement. In this case, FISH was falsely negative because of interference by benign reactive nuclei. After correcting for these cases, ALK IHC was 93% sensitive and 100% specific as compared with FISH.
ALK IHC improves the detection of ALK rearrangements when used together with FISH, and its use in lung ACA genetic testing algorithms should be considered.
ALK 基因重排在大约 5%的肺腺癌(ACAs)中发生,导致间变性淋巴瘤激酶(ALK)过表达,并预测对靶向治疗的反应。荧光原位杂交(FISH)是检测肺 ACA 中 ALK 重排的标准程序,但需要专门的设备和专业知识。ALK 蛋白过表达的免疫组织化学(IHC)是一种很有前途的筛选方式,有报道称新型抗体对 ALK 重排的肺 ACA 具有出色的敏感性和特异性。
本研究分析了来自我们临床服务的 186 例病例的 ALK IHC(5A4 克隆),并将其与 ALK FISH 以及 EGFR 和 KRAS 突变状态进行了比较。
12 例病例的 ALK 蛋白过表达和 FISH 检测到的 ALK 重排结果一致。3 例 ALK 重排病例缺乏 ALK 蛋白表达。在这些不一致的病例中,1 例存在共存的 EGFR 突变和一个微妙的非典型 ALK 重排,表现为 FISH 探针 5'着丝粒部分的断裂。1 例存在共存的 BRAF 突变。对转移灶的后续检测显示 ALK 重排缺失,但 BRAF 突变持续存在。在 1 例 ALK 重排蛋白阴性病例中,用于 ALK IHC 的组织非常有限,这增加了由于蛋白表达异质性而导致假阴性的可能性。重要的是,在最初认为没有 ALK 重排的 1 例病例中检测到了 ALK 蛋白表达。在这种情况下,由于良性反应性核的干扰,FISH 检测结果为假阴性。在纠正了这些病例后,与 FISH 相比,ALK IHC 的敏感性为 93%,特异性为 100%。
ALK IHC 与 FISH 联合使用可提高 ALK 重排的检测率,因此应考虑将其用于肺 ACA 基因检测算法。